UNITED STATES




OMB APPROVAL

OMB Number: 3235-0416

Expires: March 31, 2007

Estimated average burden

hours per response   182.00


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



Form 10-QSB


[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the quarterly period ended September 30, 2005


OR


[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from _____to ______


Commission file number: 000-30536



TotalMed, Inc.

(Exact name of registrant as specified in its charter)



              Delaware                                                                                                                        22-3530573

 (State or other jurisdiction of                                                                                                   (I.R.S. Employer

 incorporation or organization)                                                                                                  Identification No.)


162 M Homestead Street, Manchester, CT                                                                                         06040

  (Address of principal executive offices)                                                                                         (Zip-Code)



Registrant's telephone number, including area code: (860) 805-0701


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes [X]   No [  ]


Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act.)  [X] Yes [ ] No


The number of outstanding shares of the registrant's Common Stock, par value $.0001 per share, was 5,202,890 on September 30, 2005.

Transitional Small Business Disclosure format (check one):  Yes [  ]  No [X]


SEC 2334 (9-05)

Potential persons who are to respond to the collection of information contained in this form are not

required  to  respond unless the  form displays a currently valid OMB control number.




1






TotalMed, Inc.

Quarterly Report on Form 10-QSB

For the Quarter Ended on September 30, 2005


Table of Contents




PART I - FINANCIAL INFORMATION


Item 1.  Consolidated Financial Statements (Unaudited)



               Consolidated Balance Sheets as of September 30, 2005 and December 31, 2004

3


               Consolidated Statement of Operations for the Period Ending September 30, 2005

4


               Consolidated Statement of Stockholders' Equity for the Period August 7, 1997 (Inception)

5

                    to September 30, 2005


               Consolidated Statement of Cash Flows for the Period Ending September 30, 2005

7


               Notes to Consolidated Financial Statements

8


Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

10


Item 3.  Controls and Procedures

11



PART II - OTHER INFORMATION



Item 1.  Legal Proceedings

12


Item 2.  Changes in Securities and Use of Proceeds

12


Item 3.  Defaults Upon Senior Securities

12


Item 4.  Submission of Matters to a Vote of Security Holders

12


Item 5.  Other Information

12


Item 6.  Exhibits

12


SIGNATURES

13











2






PART I - FINANCIAL INFORMATION


Item 1.  Financial Statements


TOTALMED, INC. AND SUBSIDIARIES

(FORMERLY FONECASH, INC. AND SUBSIDIARIES)

(A Development Stage Company)

Consolidated Balance Sheets

      

ASSETS

      
  

September 30,

  

December 31,

  

2005

  

2004

Current assets:

     

    Cash

$

47

 

$

1,192

    Loan receivable

 

--

  

1,200

Total Current Assets

 

47

  

2,392

      

Total Assets

$

47

 

$

2,392

      

LIABILITIES AND STOCKHOLDERS' DEFICIT

      

Current liabilities:

     

    Accounts payable

$

489,856

 

$

456,166

    Due to officer/stockholder

 

636,743

  

636,743

    Notes payable

 

292,981

  

295,881

Total Current Liabilities

 

1,419,580

  

1,388,790

      
      
      

Stockholders' deficit :

     

    Preferred stock; $.0001 par value; authorized -

     

        10,000,000 shares; issued - none

 

--

  

--

    Common stock; $.0001 par value; authorized -

     

        500,000,000 shares; issued and outstanding -

     

        5,202,890 shares in 2005 and 5,553,704 in 2004

 

520

  

555

    Additional paid-in capital

 

4,431,990

  

4,420,905

    Treasury stock, 500 shares at cost

 

(1,500)

  

(1,500)

    Deficit accumulated during the development stage

 

(5,850,543)

  

(5,806,358)

Total Stockholders' (Deficit)

 

(1,419,533)

  

(1,386,398)

Total Liabilities and Stockholders' (Deficit)

$

47

 

$

2,392



The accompanying note is an integral part of these financial statements.



3






TOTALMED, INC. AND SUBSIDIARIES

(FORMERLY FONECASH, INC. AND SUBSIDIARIES)

(A Development Stage Company)

Consolidated Statements of Operations

               
  

Three Months

  

Nine Months

  

Aug. 7, 1997

  

Ended

  

Ended

  

(Inception) to

  

September 30,

  

September 30,

  

September 30,

  

2005

  

2004

  

2005

  

2004

  

2005

Revenue:

              

  Sales

$

--

 

$

--

 

$

--

 

$

--

 

$

10,840

  Cost of sales

 

--

  

--

  

--

  

--

  

5,662

    Gross profit

 

--

  

--

  

--

  

--

  

5,178

  Interest income

 

--

  

--

  

--

  

--

  

5,257

    Total revenue

 

--

  

--

  

--

  

--

  

10,435

Costs and expenses:

              

  Depreciation

 

--

  

--

  

--

  

--

  

210,426

  Amortization

 

--

  

--

  

--

  

--

  

4,118

  Research and development, related party

 

--

  

--

  

--

  

--

  

432,256

  Officer's compensation

 

--

  

--

  

1,250

  

52,500

  

1,138,320

  Impairment of investment in related party

 

--

  

--

  

--

  

--

  

50,000

  Impairment of investment in subsidiaries

 

--

  

--

  

--

  

--

  

450,000

  Loss on disposition of assets

 

--

     

--

  

--

  

11,449

  SEC litigation settlement

 

--

     

--

  

--

  

110,977

  General and administrative

 

11,308

  

11,620

  

42,935

  

18,824

  

3,453,432

  

11,308

  

11,620

  

44,185

  

71,324

  

5,860,978

Net loss

$

(11,308)

 

$

(11,620)

 

$

(44,185)

 

$

(71,324)

 

$

(5,850,543)

               

Basic and diluted loss per common share

$

(0.002)

 

$

(0.002)

 

$

(0.009)

 

$

(0.014)

   

Weighted average common shares outstanding

 

5,202,890

  

4,928,704

  

5,024,122

  

4,928,704

   


The accompanying note is an integral part of these financial statements.





4







TOTALMED, INC. AND SUBSIDIARIES

(FORMERLY FONECASH, INC. AND SUBSIDIARIES)

(A Development Stage Company)

Consolidated Statements of Changes in Stockholders' Equity

For the Period August 7, 1997 (Inception) to September 30, 2005

                

Deficit

                

Accumulated

       

Additional

        

During the

 

Common Stock

  

Paid-in

  

Treasury Stock

  

Development

 

Shares

 

 

Amount

  

Capital

  

Shares

 

 

Amount

  

Stage

 

 

  

 

  

 

  

 

  

 

  

 

Balances, August 7, 1997 (inception)

-

 

$

-

 

$

-

  

-

 

$

-

 

$

-

    Common stock issued for services

                

        and costs advanced, valued at

                

        $.0001 per share

2,000,000

  

200

  

-

  

-

  

-

  

-

    Common stock issued for services,

                

        valued at $.15 per share

200,000

  

20

  

29,980

  

-

  

-

  

-

    Net loss for the period

               

(61,404)

                 

Balances, December 31, 1997

2,200,000

  

220

  

29,980

  

-

  

-

  

(61,404)

                 

    Sale of common stock ($.4156 per share)

204,500

  

20

  

84,965

  

-

  

-

  

-

    Net loss

               

(95,211)

                 

Balances, December 31, 1998

2,404,500

  

240

  

114,945

  

-

  

-

  

(156,615)

                 

    Sale of common stock ($.7622 per share)

1,098,505

  

110

  

837,160

  

-

  

-

  

-

    Services contributed by the

                

        president of the Company

-

  

-

  

60,000

  

-

  

-

  

-

    Common stock issued for services,

                

        valued at $.81 per share

333,333

  

33

  

269,967

  

-

  

-

  

-

    Net loss

               

(785,366)

                 

Balances, December 31, 1999

3,836,338

  

383

  

1,282,072

  

-

  

-

  

(941,981)

    Sale of common stock ($1.25 per share)

25,000

  

3

  

31,247

  

-

  

-

  

-

    Common stock issued for services,

                

        valued at $.11 per share

1,466,667

  

147

  

157,353

  

-

  

-

  

-

    Common stock issued for services,

                

        valued at $.5312 per share

623,367

  

62

  

331,071

  

-

  

-

  

-

    Purchase of treasury stock

-

  

-

  

-

  

500

  

(1,500)

  

-

    Net loss

               

(897,368)

Balances, December 31, 2000

5,951,372

  

595

  

1,801,743

  

500

  

(1,500)

  

(1,839,349)


The accompanying note is an integral part of these financial statements.




5







TOTALMED, INC. AND SUBSIDIARIES

(FORMERLY FONECASH, INC. AND SUBSIDIARIES)

(A Development Stage Company)

Consolidated Statements of Changes in Stockholders' Equity

For the Period August 7, 1997 (Inception) to September 30, 2005

                

Deficit

                

Accumulated

       

Additional

        

During the

 

Common Stock

  

Paid-in

  

Treasury Stock

  

Development

 

Shares

 

 

Amount

  

Capital

  

Shares

 

 

Amount

  

Stage

    Common stock issued for services,

                

        valued at $.12 per share

6,959,708

  

696

  

858,080

  

-

  

-

  

-

    Sale of common stock ($.017 per share)

1,087,976

  

109

  

17,891

  

-

  

-

  

-

    Common stock issued in acquisition

                

        of subsidiaries, valued at $.50 per share

900,000

  

90

  

449,910

  

-

  

-

  

-

    Net loss

               

(1,878,498)

Balances, December 31, 2001

14,899,056

  

1,490

  

3,127,624

  

500

  

(1,500)

  

(3,717,847)

    Sale of common stock ($.012 per share)

10,746,826

  

1,074

  

122,878

  

-

  

-

  

-

    Common stock issued for services,

                

        valued at $.03 per share

32,928,174

  

3,293

  

1,123,851

  

-

  

-

  

-

    Net loss

               

(1,857,167)

RESTATED FROM THIS POINT FORWARD


Balances, December 31, 2002

2,928,704

  

293

  

4,379,917

  

500

  

(1,500)

  

(5,575,014)

    Common stock issued for services,

850,000

  

85

  

16,915

  

-

  

-

  

-

        valued at $.001 per share

                

    Common stock issued as repayment of

1,150,000

  

115

  

22,885

  

-

  

-

  

-

        related party debt

                

        valued at $.001 per share

                

    Net loss

               

(126,307)

Balances, December 31, 2003

4,928,704

  

493

  

4,419,717

  

500

  

(1,500)

  

(5,701,321)

    Common stock issued for services,

625,000

  

63

  

1,188

  

-

  

-

  

-

        valued at $.0001 per share

                

    Net loss

               

(105,037)

Balances, December 31, 2004

5,553,704

  

555

  

4,420,905

  

500

  

(1,500)

  

(5,806,358)

    Common stock issued for services,

625,000

  

63

  

1,188

  

-

  

-

  

-

        valued at $.0001 per share

                

    Common stock issued as repayment of

1,500,000

  

150

  

9,650

  

-

  

-

  

-

        debt, valued at $.003 per share

                

    Common stock retired

(2,475,819)

  

(248)

  

247

  

-

  

-

  

-

    Additional shares due to stock split

6

        

-

  

-

  

-

    Net loss for the period

               

(44,185)

Balances, September 30, 2005

5,202,890

 

$

520

 

$

4,431,990

  

500

 

$

(1,500)

 

$

(5,850,543)


The accompanying note is an integral part of these financial statements.




6







TOTALMED, INC. AND SUBSIDIARIES

(FORMERLY FONECASH, INC. AND SUBSIDIARIES)

(A Development Stage Company)

Consolidated Statements of Cash Flows

         
  

Nine

  

Nine

  

Aug. 7, 1997

  

Months Ended

  

Months Ended

  

(Inception) to

  

September 30,

  

September 30,

  

September 30,

  

2005

  

2004

  

2005

Cash flows from operating activities:

        

    Net loss

$

(44,185)

 

$

(71,324)

 

$

(5,850,543)

    Adjustments to reconcile net loss to net

        

         cash used in operating activities

        

         Depreciation

 

--

  

--

  

210,426

         Amortization

 

--

  

--

  

4,118

         Common stock issued for services

 

1,250

  

--

  

2,854,253

         Common stock issued in acquisition of subsidiaries

 

--

  

--

  

450,000

         Common stock issued to an officer in payment of debt

 

--

  

--

  

23,000

         Notes issued for payment of expenses

 

--

  

--

  

41,280

         Write-down of lost inventory

 

--

  

--

  

204,338

         Write off uncollectible accounts

 

--

  

--

  

10,840

         Loss on disposition of assets

 

--

  

--

  

11,449

         Changes in assets and liabilities

        

            Increase in accounts receivable

 

--

  

--

  

(10,840)

            (Increase) decrease in inventory

 

--

  

--

  

(204,338)

            Increase in accounts payable

 

33,690

  

3,796

  

489,856

    Net cash used in operating activities

 

(9,245)

  

(67,528)

  

(1,766,161)

         

Cash flows from investing activities:

        

    Payments on notes receivable

 

--

  

--

  

(1,200)

    Repayments on notes receivable

 

1,200

  

--

  

1,200

    Organization costs

 

--

  

--

  

(368)

    Purchases of property and equipment

 

--

  

--

  

(220,625)

    Acquisition of patent rights

 

--

  

--

  

(5,000)

    Net cash provided by (used in) investing activities

 

1,200

  

--

  

(225,993)

         

Cash flows from financing activities:

        

    Proceeds from short-term debt

 

6,900

  

30,000

  

324,849

    Repayment of short-term debt

 

--

  

--

  

(63,348)

    Increase in amounts

        

       due to an officer/stockholder

 

--

  

52,500

  

636,743

    Purchase of treasury stock

 

--

  

--

  

(1,500)

    Proceeds from sale of common stock

 

--

  

--

  

1,095,457

    Net cash provided by financing activities

 

6,900

  

82,500

  

1,992,201

         

Net increase (decrease) in cash

 

(1,145)

  

14,972

  

47

Cash at beginning of period

 

1,192

  

--

  

--

Cash at end of period

$

47

 

$

14,972

 

$

47

         






The accompanying note is an integral part of these financial statements.



7






TOTALMED, INC. AND SUBSIDIARIES

(A Development Stage Company)

Form 10QSB

Quarter Ended September 30, 2005

Note to Consolidated Financial Statements


Note 1 – Condensed Consolidated Financial Statements


Basis of Presentation


The accompanying interim unaudited consolidated financial statements include the accounts of TotalMed, Inc. and its subsidiaries which are hereafter referred to as (the "Company"). All intercompany accounts and transactions have been eliminated in consolidation. These financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-QSB of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, such interim statements reflect all adjustments (consisting of normal recurring accruals) necessary to present fairly the financial position and the results of operations and cash flows for the interim periods presented. The results of operations for these interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2005. These financial statements should be read in conjunction with the audited financial statements and footnotes included in the Company's report on Form 10-KSB for the year ended December 31, 2004.


Description of Business


The financial statements presented are those of TotalMed, Inc. and its subsidiaries, a development stage company (the “Company”).  The Company was incorporated under the laws of the State of Delaware on August 7, 1997.  The Company's activities during the nine months ended September 30, 2005 have been primarily directed towards the raising of capital.  The Company’s initial business activity was to acquire the rights to market a patented electronic terminal that was to be used by retail merchants and in-home salespersons when payment was made with a credit or debit card.  Currently the Company is seeking a merger candidate.


The Company has limited operations and in accordance with Statement of Financial Accounting Standards No. 7 (SFAS #7), the Company is considered a development stage company.


Use of Estimates in the Preparation of Financial Statements


The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reporting amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates.


Loss Per Common Share


Loss per common share is computed by dividing the net loss by the weighted average shares outstanding during the period. The 2004 weighted average shares outstanding were restated to reflect the reverse stock split.




8






TOTALMED, INC. AND SUBSIDIARIES

(A Development Stage Company)

Form 10QSB

Quarter Ended September 30, 2005

Note to Consolidated Financial Statements


Notes Payable


The Company received an additional $1,800 proceeds for a note during the quarter ended March 31, 2005. That note was then converted into 30,000,000 shares of common stock.  The Company also received an additional $1,600 and $3,500 proceeds for a 6% demand note during the quarters ended September 30, 2005 and June 30, 2005, respectively.


Common Stock


Two former directors of the company returned 49,516,387 shares of stock to the company. On May 11, 2005 there was a reverse stock split of the common stock of the Company on the basis of one share for each 20 shares outstanding with shareholders of record as of March 1, 2005.  The number of common shares outstanding as a result of the reverse stock split was 5,202,890.  The December 31, 2004 Common Stock and Additional Paid in Capital balances were restated to reflect the reverse stock split.







9






Item 2.  Management's Discussion and Analysis


This Quarterly Report on Form 10-QSB, including the information incorporated by reference herein, includes "forward looking statement" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Act") and Section 21E of the Securities Act of 1934, as amended ("Act of 34"). All of the statements contained in this Quarterly Report on Form 10-QSB, other than statements of historical fact, should be considered forward looking statements, including, but not limited to, those concerning the Company's strategies, objectives and plans for expansion of its operation, products and services and growth in demand for it's products and services. There can be no assurances that these expectations will prove to have been correct. Certain important factors that could cause actual results to differ materially from the Company's expectations (the "Cautionary Statements") are disclosed in this Quarterly report on Form 10-QSB. All subsequent written and oral forward looking statements by or attributable to the Company or persons acting on behalf are expressly qualified in their entirety by such Cautionary Statements. Investors are cautioned not to place undue reliance on these forward looking statements which speak only as of the date hereof and are not intended to give any assurance as to future results. The Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or reflect the occurrence of unanticipated events.


TotalMed, Inc., f/k/a Fonecash, Inc. (the "Company") was incorporated under the laws of the State of Delaware on August 7, 1997 and is in its development stage.  On May 11, 2005, the Company changed its name from FoneCash, Inc. to TotalMed, Inc.  The Company currently has no ongoing business operation and is actively seeking a potential merger or acquisition candidate.  The Company has not yet found such a candidate and as of this date no negotiations have been conducted with any potential candidate.


The Company incurred operating losses of $(5,850,543) from inception to September 30, 2005.  The Company expects its accumulated deficit to grow for the foreseeable future as total costs and expenses continue without any revenue or business activity.  There can be no assurances that the Company will locate a potential merger or acquisition candidate or that if such a candidate is located that management can successfully negotiate and consummate a business combination with any such entity.


General


TotalMed, Inc. f/k/a Fonecash, Inc. (the "Company") was incorporated under the laws of the State of Delaware on August 7, 1997.  During the fourth quarter of December 2002, the Company began to wind down its operations.  This occurred because of management’s inability to raise sufficient funds to finance the continued development of the Company’s business plan.


Until that point, the Company had been engaged in the payment processing of transactions for banks and their merchants through its terminals and proprietary system. As part of that operation, the Company was developing a wired and wireless gateway to convert consumers' credit and debit card information collected by mobile merchants into a format that can be processed by banks.  The Company intended to act as a payment system service provider between banks, mobile merchants and their customers.  The Company intended to charge merchants a fixed transaction fee to process their payments.


Currently, the Company remains in development stage and it has no operating profits to date.  With the cessation of its pursuit of the credit card processing business, the Company currently has no business operations. The Company is actively seeking a possible merger candidate in an effort to provide shareholders value.


The Company incurred an operating loss of $11,308 during the three month period ended September 30, 2005 compared to a loss of $11,620 during the same period in 2004.  The Company incurred an operating loss of $44,185 during the nine month period ended September 30, 2005 compared to a loss of $71,324 during the same period in 2004.  This decrease in the Company’s operating loss of $27,139 was attributable to a reduction of Officer’s compensation expenses of $51,250 and an increase in General and Administrative expense of $24,111 which was caused by the increased expense of reestablishing the company’s reporting



10






status.  The Company spent a total of $432,256 on Research and Development from Inception to September 30, 2005.  The Company expects its accumulated deficit to grow for the foreseeable future.


The Company's Operations to Date


The Company was developing a system of processing credit cards for an under served community of low volume merchants and in-home salespersons consisting of a fixed wire or wireless terminal and a system of computers, utilizing established communications networks, both wired and wireless, for processing the data from credit and debit cards. The Company ceased this operation during the fourth quarter of 2002.


The Company has never operated under name other than as reported above, nor has it ever been involved with any bankruptcy, receivership or similar proceeding or engaged in any material reclassification, merger, consolidation, or purchase or sale of assets.


Results of Operation


General and administrative expenses during the three month period ending September 30, 2005 were $11,308 as compared to $11,620 for the same period in 2004.

 

General and administrative expenses during the nine month period ending September 30, 2005 were $42,935 as compared to $18,824 for the same period in 2004, representing an increase of $24,111.  This increase was caused by the costs associated with maintaining the Company’s reporting status.


Balance Sheet Data


The Company's combined cash and cash equivalents totaled $ 47 for the period ending September 30, 2005 compared to $1,192 the same period in 2004.  This decrease was attributable to the Company having increased expenses.


The Company does not expect to generate a positive internal cash flow for at least the next six months due to it having no current revenue generating activities.


Property and equipment was valued at $0 the period ending September 30, 2005 which is the same amount as in 2004 for the same period.


Item 3. Controls and Procedures


As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s principal executive officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-14.  Based upon that evaluation, the principal executive officer concluded that the Company’s disclosure controls and procedures are effective in timely alerting them to material information relating to the Company required to be included in the Company’s periodic SEC filings. As such no changes were made in controls and procedures.






11







PART II - OTHER INFORMATION



Item 1.  Legal Proceedings


The Company was served with a summons and complaint for failure to pay the monthly payments on its line of credit with Fleet National Bank.  Pursuant to the lawsuit, the Company would be liable to Fleet National Bank for the outstanding principal balance of $107,645 plus attorney’s fees.  Management has indicated its intentions to defend the action and will repay the principal balance in monthly installments upon receipt of capital contributions from investors.


On April 8, 2002 the Securities and Exchange Commission filed a complaint alleging that a registration statement and amendments, filed with the Commission by the Company in December 2001, January 2002 and March 2002, and signed by the former president of the Company, Daniel E. Charboneau, contained material misrepresentations and omissions.  On January 6, 2004, a United States District Judge from the District of Columbia entered a default judgment against the Company restraining the Company from further violations of Section 17(a) of the Securities Act of 1933, Sections 10(b) and 13a-13 of the Securities Exchange Act of 1934 and Rules 10b-5, 12b-20, 13a-1 and 13a-13 thereunder.  As part of this order the Court also ordered penalties and interest in the amount of $110,977.


Item 2.  Changes in Securities


None


Items 3.  Defaults upon Senior Securities


             None


Item 4.  Submission of Matters to a Vote of Security Holders


None


Item 5.   Other Information


              None



Item  6.  Exhibits.


(a)  Exhibits.


Exhibit 31.1 – Certification required by Rule 13a-14(a) or Rule 15d-14(a),

Exhibit 32.1 – Certification Required by Rule 13a-14(b) or Rule 15d-14(b) and section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350




12








Signatures


In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned who is duly authorized to sign as an officer and as the principal officer of the Company.


TotalMed, Inc


By:      /s/ Abraham Pierce

         ---------------------------------------------------------

         Abraham Pierce, Chairman/CEO


Date:    November 16, 2005









13